These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 17508493)
1. The treatment of viral infections and nonmelanoma skin cancers. Del Rosso JQ Cutis; 2007 Apr; 79(4 Suppl):29-35. PubMed ID: 17508493 [TBL] [Abstract][Full Text] [Related]
2. Viral and nonviral uses of imiquimod: a review. Gupta AK; Cherman AM; Tyring SK J Cutan Med Surg; 2004; 8(5):338-52. PubMed ID: 15868314 [TBL] [Abstract][Full Text] [Related]
3. Imiquimod - Its role in the treatment of cutaneous malignancies. Bubna AK Indian J Pharmacol; 2015; 47(4):354-9. PubMed ID: 26288465 [TBL] [Abstract][Full Text] [Related]
4. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073 [TBL] [Abstract][Full Text] [Related]
5. Beyond a decade of 5% imiquimod topical therapy. A Gaspari A; Tyring SK; Rosen T J Drugs Dermatol; 2009 May; 8(5):467-74. PubMed ID: 19537370 [TBL] [Abstract][Full Text] [Related]
6. Do lasers or topicals really work for nonmelanoma skin cancers? Brightman L; Warycha M; Anolik R; Geronemus R Semin Cutan Med Surg; 2011 Mar; 30(1):14-25. PubMed ID: 21540017 [TBL] [Abstract][Full Text] [Related]
7. Topical imiquimod in the treatment of two cutaneous melanocytomas in a dog. Coyner K; Loeffler D Vet Dermatol; 2012 Apr; 23(2):145-9, e31. PubMed ID: 21777307 [TBL] [Abstract][Full Text] [Related]
8. The role of topical immune response modifiers in skin cancer. Woodmansee C; Pillow J; Skinner RB Drugs; 2006; 66(13):1657-64. PubMed ID: 16978032 [TBL] [Abstract][Full Text] [Related]
9. Role of topical therapies in the management of cutaneous disease. Skinner R J Cutan Med Surg; 2004; 8 Suppl 3():22-31. PubMed ID: 15647859 [TBL] [Abstract][Full Text] [Related]
10. Imiquimod induces sustained remission of actinic damage: a case report spanning one decade of observation. Knackstedt TJ; Quitadamo M Cutis; 2015 Feb; 95(2):E20-3. PubMed ID: 25750973 [TBL] [Abstract][Full Text] [Related]
12. Topical imiquimod to treat intraepidermal carcinoma. Hengge UR; Stark R Arch Dermatol; 2001 Jun; 137(6):709-11. PubMed ID: 11405756 [No Abstract] [Full Text] [Related]
13. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod. Papakostas D; Stockfleth E Future Oncol; 2015 Nov; 11(22):2985-90. PubMed ID: 26450707 [TBL] [Abstract][Full Text] [Related]
14. Imiquimod as an antiaging agent. Metcalf S; Crowson AN; Naylor M; Haque R; Cornelison R J Am Acad Dermatol; 2007 Mar; 56(3):422-5. PubMed ID: 17184874 [TBL] [Abstract][Full Text] [Related]
15. Imiquimod cream 5% for the treatment of arsenic-induced cutaneous neoplasms. Lonergan CL; McNamara EK; Cordoro KM; Greer KE Cutis; 2010 Apr; 85(4):199-202. PubMed ID: 20486460 [TBL] [Abstract][Full Text] [Related]
16. Treatment of extramammary Paget disease with topical imiquimod cream: case report and literature review. Cohen PR; Schulze KE; Tschen JA; Hetherington GW; Nelson BR South Med J; 2006 Apr; 99(4):396-402. PubMed ID: 16634252 [TBL] [Abstract][Full Text] [Related]